Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2127)
11/02/2019
Indication
In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Comments
None
Link to Advice
Advice Published
11/02/2019
SMC Submission Type
Full
SMC Status
Not recommended